Table: Solasia Pharma -6-MTH group results (IFRS)

Solasia Pharma KK

10/08/2017 07:30

Aug 10 (Reuters)-  
              Solasia Pharma K. K.  
              CONSOLIDATED FINANCIAL HIGHLIGHTS  
     (in billions of yen unless specified)  
                   6 months ended      6 months ended        Year to   
                  Jun 30, 2017        Jun 30, 2016      Dec 31, 2017   
                     LATEST             YEAR-AGO           COMPANY     
                     RESULTS             RESULT           FORECAST     
  Sales               5 mln              201 mln           423 mln     
                   (-97.2 pct)                           (-15.6 pct)   
  Operating       loss 553 mln        loss 254 mln        loss 1.79    
  Pretax          loss 558 mln        loss 266 mln        loss 1.79    
  Net             loss 545 mln        loss 261 mln        loss 1.80    
  EPS Basic       loss 7.11 yen      loss 10.61 yen    loss 23.44 yen  
  EPS Diluted     loss 7.11 yen      loss 10.61 yen                    
  Ann Div                                  NIL               NIL       
  -Q2 Div              NIL                 NIL                         
  -Q4 Div                                  NIL               NIL       
  
  NOTE - Solasia Pharma K. K..  
  (Figures are reported based on international accounting rules (IFRS).)  
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half  
  dividend and Q4 to the second-half dividend announced before a new corporate law in  
  2006 allowed companies to pay and report dividends on a quarterly basis. 
  *Net - represents Net profit attributable to owners of the parent company.  
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4597.T 
  ((Tokyo Headline News Desk +813 6441 1812))